Freedman MS - Search Results

1

Detecting cognitive fatigue in multiple sclerosis: method matters.

Walker LA, Berard JA, Berrigan LI, Rees LM, Freedman MS. Walker LA, et al. Among authors: freedman ms. J Neurol Sci. 2012 May 15;316(1-2):86-92. doi: 10.1016/j.jns.2012.01.021. Epub 2012 Feb 14. J Neurol Sci. 2012. PMID: 22336698

2

Vascular headache: a presenting symptom of multiple sclerosis.

Freedman MS, Gray TA. Freedman MS, et al. Can J Neurol Sci. 1989 Feb;16(1):63-6. doi: 10.1017/s0317167100028523. Can J Neurol Sci. 1989. PMID: 2924210

3

Meaningful change in cognition in multiple sclerosis: method matters.

Walker LA, Mendella PD, Stewart A, Freedman MS, Smith AM. Walker LA, et al. Among authors: freedman ms. Can J Neurol Sci. 2011 Mar;38(2):282-8. doi: 10.1017/s0317167100011471. Can J Neurol Sci. 2011. PMID: 21320834

4

Activation patterns in multiple sclerosis on the Computerized Tests of Information Processing.

Smith AM, Walker LA, Freedman MS, Berrigan LI, St Pierre J, Hogan MJ, Cameron I. Smith AM, et al. Among authors: freedman ms. J Neurol Sci. 2012 Jan 15;312(1-2):131-7. doi: 10.1016/j.jns.2011.08.003. Epub 2011 Aug 21. J Neurol Sci. 2012. PMID: 21862036 Clinical Trial.

5

Cognitive change and neuroimaging following immunoablative therapy and hematopoietic stem cell transplantation in multiple sclerosis: A pilot study.

Walker LA, Berard JA, Atkins HL, Bowman M, Lee H, Freedman MS. Walker LA, et al. Among authors: freedman ms. Mult Scler Relat Disord. 2014 Jan;3(1):129-35. doi: 10.1016/j.msard.2013.05.001. Epub 2013 Jun 5. Mult Scler Relat Disord. 2014. PMID: 25877984

6

The use of disease-modifying agents in multiple sclerosis--by the Canadian Network of MS Clinics.

O'Connor P, Devonshire V; Canadian Network of MS Clinic. O'Connor P, et al. Can J Neurol Sci. 2008 May;35(2):127-32. Can J Neurol Sci. 2008. PMID: 18574923 English, French. No abstract available.

7

Canadian treatment optimization recommendations (TOR) as a predictor of disease breakthrough in patients with multiple sclerosis treated with interferon beta-1a: analysis of the PRISMS study.

Freedman MS, Forrestal FG. Freedman MS, et al. Mult Scler. 2008 Nov;14(9):1234-41. doi: 10.1177/1352458508093892. Epub 2008 Jul 16. Mult Scler. 2008. PMID: 18632774

8

Anti-alpha-glucose-based glycan IgM antibodies predict relapse activity in multiple sclerosis after the first neurological event.

Freedman MS, Laks J, Dotan N, Altstock RT, Dukler A, Sindic CJ. Freedman MS, et al. Mult Scler. 2009 Apr;15(4):422-30. doi: 10.1177/1352458508101944. Mult Scler. 2009. PMID: 19324980 Free PMC article.

9

Treatment options for patients with multiple sclerosis who have a suboptimal response to interferon-β therapy.

Freedman MS. Freedman MS. Eur J Neurol. 2014 Mar;21(3):377-87, e18-20. doi: 10.1111/ene.12299. Epub 2013 Nov 15. Eur J Neurol. 2014. PMID: 24237582 Free article. Review.

10

Mechanism of gammadelta T cell-induced human oligodendrocyte cytotoxicity: relevance to multiple sclerosis.

Zeine R, Pon R, Ladiwala U, Antel JP, Filion LG, Freedman MS. Zeine R, et al. Among authors: freedman ms. J Neuroimmunol. 1998 Jul 1;87(1-2):49-61. doi: 10.1016/s0165-5728(98)00047-2. J Neuroimmunol. 1998. PMID: 9670845

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

324 results

Search Page